I guess we will need to wait and see what the analysis review has to say. This quote is pretty serious and I wonder why this review wasn't done before now as none of this is really news. "Accordingly, the Company has engaged a specialised global healthcare intelligence group to undertake an analysis on the potential future risks to the addressable market for Presendin™ for IIH. The results of the analysis will be available in mid Q3 CY2023. The Board will then be in a position to fully assess the market opportunity for Presendin™ in IIH in light of new GLP-1RAs including Ozempic® and Wegovy® and whether to continue with the revised protocol change for the IIH EVOLVE Phase III clinical trial."
- Forums
- ASX - By Stock
- IXC
- Ann: Phase III Clinical Trial Update and New IIH Market Analysis
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-53
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.8¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.062 |
1 | 15500 | 0.061 |
1 | 150000 | 0.060 |
1 | 100000 | 0.052 |
1 | 60001 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 10000 | 1 |
0.069 | 16500 | 1 |
0.070 | 40000 | 1 |
0.076 | 888 | 1 |
0.083 | 4000 | 1 |
Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable